Adventures in mRNA lipid nanoparticle formulation

Lipid nanoparticles (LNPs) encapsulating neoantigen-encoding mRNA hold promise for the development of more potent therapeutic cancer vaccines. As a lab focused on optimizing personalized cancer treatments, establishing that we are able to formulate and effectively utilize such particles would be a step towards initiating a clinical trial, and the first stages of this translational process often involve generating data that demonstrate efficacy in vitro.